Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation during osimertinib treatment
2020-003512-27Phase 2Active
- Sponsor
- AIO-Studien
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AIO-Studien. Primary endpoint: Safety and tolerability. Started Aug 2021; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-003512-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003512-27.